The global alpha emitter market size reached US$ 1.47 billion in 2023. Looking forward, the market is projected to reach US$ 10.97 billion by 2032, exhibiting a growth rate (CAGR) of 24.97% during 2023-2032.
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues.
Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
2. What is the expected growth rate of the global alpha emitter market during 2024-2032?
3. What are the key factors driving the global alpha emitter market?
4. What has been the impact of COVID-19 on the global alpha emitter market?
5. What is the breakup of the global alpha emitter market based on the type of radionuclide?
6. What is the breakup of the global alpha emitter market based on the medical application?
7. What are the key regions in the global alpha emitter market?
8. Who are the key players/companies in the global alpha emitter market?
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues.
Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
Alpha Emitter Market Trends
The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively.The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global alpha emitter market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on type of radionuclide, medical application, and end user.Breakup by Type of Radionuclide:
- Astatine
- Radium
- Actinium
- Lead
- Bismuth
- Others
Breakup by Medical Application:
- Prostate Cancer
- Bone Metastasis
- Ovarian Cancer
- Pancreatic Cancer
- Endocrine Tumors
- Others
Breakup by End User:
- Hospitals
- Medical Research Institutions
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.Key Questions Answered in This Report
1. What was the size of the global alpha emitter market in 2023?2. What is the expected growth rate of the global alpha emitter market during 2024-2032?
3. What are the key factors driving the global alpha emitter market?
4. What has been the impact of COVID-19 on the global alpha emitter market?
5. What is the breakup of the global alpha emitter market based on the type of radionuclide?
6. What is the breakup of the global alpha emitter market based on the medical application?
7. What are the key regions in the global alpha emitter market?
8. Who are the key players/companies in the global alpha emitter market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Alpha Emitter Market
6 Market Breakup by Type of Radionuclide
7 Market Breakup by Medical Application
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Actinium Pharmaceuticals Inc.
- Alpha Tau Medical Ltd.
- Bayer AG
- Fusion Pharmaceuticals
- IBA RadioPharma Solutions
- RadioMedix Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.47 Billion |
| Forecasted Market Value ( USD | $ 10.97 Billion |
| Compound Annual Growth Rate | 24.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
